Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

Inclusion Criteria * Subject has undergone previous nephrectomy. * Subject has received at least 2 cycles (12 weeks) of treatment with sunitinib for RCC and stopped therapy due to progressive disease within 100 days prior to screening. * Subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST. * ECOG Performance Score of 0-1. * No history of another active cancer within the past 5 years.Life expectancy of at least 4 months. * Willing to take adequate measures to prevent pregnancy. Exclusion Criteria * Subject has received anti-cancer therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to study drug administration. * Subject has untreated brain or meningeal metastases. * Subject has received a tyrosine kinase inhibitor (TKI) other than sunitinib or sorafenib. * Prior use of Avastin is allowed. * The subject is receiving therapeutic anticoagulation therapy. * The subject has a history of/or currently exhibits clinically significant cancer related events of bleeding (e.g., hematuria, hemoptysis). * The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) \> 100 mmHg; or systolic blood pressure (BP) \> 150 mmHg. * The subject has a history of myocardial infarction within 6 months of Study Day 1. * The subject has a documented left ventricular (LV) Ejection Fraction \< 50%. * The subject has known autoimmune disease with renal involvement (eg, Lupus). * Female subjects who are pregnant or breast feeding. * Subject is receiving anti-retroviral therapy for HIV. * Subject has a clinically significant uncontrolled condition(s) including but not limited to: * active uncontrolled infection, * Class III or IV heart failure as defined by the New York Heart Association functional classification system, * unstable angina pectoris or cardiac arrhythmia, * history of adrenal insufficiency, * psychiatric illness/social situation that would limit compliance with study requirements; * Active, ulcerative colitis, Crohn's disease, celiadisease or any other conditions that interfere with absorption. * Subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.